

ANAPHYLAXIS AND GENERALISED ALLERGIC REACTION (GAR)

PRACTICE GUIDELINE [®]

KEY POINTS

Anaphylaxis has been defined as:

- Any acute onset illness with typical skin features (urticarial rash or erythema/flushing, and/or angioedema) PLUS any one or more of the following involvement:
 - respiratory
 - cardiovascular 0
 - persistent severe gastrointestinal symptoms

OR

Any acute onset of hypotension or bronchospasm or upper airway obstruction where anaphylaxis is considered possible, even if typical skin features are not present.

Generalised Allergic Reaction (GAR)

A reaction characterized by one or more symptoms or signs of skin and/or gastrointestinal tract involvement without respiratory and/or cardiovascular involvement.

Management:

- Do not allow children with anaphylaxis to stand or walk •
- Treatment of anaphylaxis is intra-muscular adrenaline 10 micrograms/kg or 0.01mL/kg of 1:1000 (maximum 0.5mL), into lateral thigh, which should be repeated after 5 minutes if the child is not improving (see anaphylaxis algorithm).
- An adrenaline autoinjector can be used if unable to calculate exact dose or to avoid • delay, including in children <1 year old (Epipen 300microg for children ≥20kg and Epipen 150microg for children 7.5-20kg)
 - Senior medical advice may be required, call for assistance as needed. \circ
 - Airway give supplemental oxygen. 0
 - If airway threatened, call emergency number:
 - Code Blue 2222 (SCH and CHW) or
 - Triple Zero 000 (HITH)

This document reflects what is currently regarded as safe practice. However, as in any clinical situation, there may be factors which cannot be covered by a single set of guidelines. This document does not replace the need for the application of clinical judgement to each individual presentation.

Approved by:	SCHN Policy, Procedure and Guideline Committee		
Date Effective:	1 st November 2019		Review Period: 3 years
Team Leader:	Fellow		Area/Dept: Allergy & Immunology
Date of Publishing: 19 Jur	ne 2020 1:14 PM	Date of Printing:	Page 1 of 16

С K:\CHW P&P\ePolicy\Jun 20\Anaphylaxis and GAR.docx

This Guideline may be varied, withdrawn or replaced at any time.



- All patients who have had an anaphylactic reaction should be observed for a minimum of 4 hours post adrenaline. Only allow to mobilise under observation \geq 1 hour after last dose of adrenaline and once all symptoms have resolved.
- For Hospital in the Home [HITH] (previously known as CAPAC), always contact the child's medical team once the child is stable.

CHANGE SUMMARY

- Due for mandatory review
- Title change replacing Anaphylaxis & Allergy Management (ED & At Home)
- 19/6/20: Minor review. Updated Loratadine dosing, in line with the AMH-CDC dosing recommendations.

READ ACKNOWLEDGEMENT

- Emergency Department CHW and SCH: Clinical staff: medical officers, nurses and pharmacists need to understand and acknowledge this document.
- HITH: Clinical nurses undertaking "Hospital In The Home" visiting need to understand • and acknowledge this document and have appropriate training in EpiPen use.
- Other Areas: Discretionary: Manager to determine which staff need to read and acknowledge this document.

This document reflects what is currently regarded as safe practice. However, as in any clinical situation, there may be factors which cannot be covered by a single set of guidelines. This document does not replace the need for the application of clinical judgement to each individual presentation.

Approved by:	SCHN Policy, Procedure a	and Guideline Committee	
Date Effective:	1 st November 2019		Review Period: 3 years
Team Leader:	Fellow		Area/Dept: Allergy & Immunology
Date of Publishing: 19	June 2020 1:14 PM	Date of Printing:	Page 2 of 16

D

K:\CHW P&P\ePolicy\Jun 20\Anaphylaxis and GAR.docx This Guideline may be varied, withdrawn or replaced at any time.



Algorithm Suspected allergic reaction Remove Allergen if still present Remove medication or insect sting if visible **CLINICAL FEATURES OF ANAPHYLAXIS** Lay patient flat OR allow to sit if breathing difficult If any ONE of the following are present Do not allow to stand or walk Difficult or Noisy Breathing Swelling of tongue Swelling/tightness in throat Difficult talking and/or hoarse voice Are any of the Clinical Wheeze or persistent cough Features for Anaphylaxis Hypotension, Persistent Dizziness or collapse present? Pale and Floppy (young children) NO YES Give Adrenaline IM into the lateral thigh Generalised Allergic Reaction (GAR) DOSE: 10microg/kg up to 0.5mL (1:1000 dilution). Use an Reaction without respiratory or EpiPen if unable to calculate exact dose or to avoid delay, cardiovascular involvement including in children <1year old **REPEAT DOSE EVERY 5 MINUTES AS NEEDED** Monitor Pulse, BP, Respiratory rate, pulse oximetry Supportive treatment** Oral non-sedating antihistamines may A: Airway = Oxygen (high flow >6L/min) be given to treat urticaria and B: Salbutamol if respiratory involvement angioedema C: If hypotensive give IV normal saline (20mL/kg) DISCHARGE FOLLOWING GAR Children presenting with GAR do not Inadequate Response or need an EpiPen. deterioration after ≥2 doses of Discharge requirements: adrenaline 1) A summary letter to the GP 2) ASCIA Action Plan for Allergic YES-NO-Reactions (green) Observation (available at www.allergy.org.au). Observe the Patient for at least 4 hours after the 3) Paediatrician in LOCAL area or 1. REQUEST ICU CONSULT dose of adrenaline Private Immunologist referral 2. Consider Adrenaline Infusion Discuss patient with Immunology team including 3. For Upper Airway Obstruction treatment and follow-up plan Nebulised adrenaline (5mL of 1:1000 dilution) Prolonged and biphasic reactions may occur Consider Intubation **Observe longer if patient:** If airway threatened call arrest on 2222 1) had a severe reaction with hypotension or 4. For persistent wheeze hypoxia OR Salbutamol via spacer or nebulizer 2) required repeated doses of adrenaline OR Corticosteroids (oral prednisolone 1-2mg/kg 3) has a history of asthma or protracted (max 60mg) or IV hydrocortisone 4mg/kg (max anaphylaxis OR 200mg)) 4) has other concomitant illness OR 5) lives remote from medical care or social concerns *Supportive Treatments Antihistamines -Antihistamines have no role in treating respiratory or cardiovascular symptoms of anaphylaxis. **DISCHARGE FOLLOWING ANAPHYLAXIS** -Oral non-sedating antihistamines may be given to treat When patient fit for discharge the patient requires: urticaria and angioedema. -IV/IM antihistamines should not be used. 1) EpiPen Prescription via arrangement with Corticosteroids Immunology team or GP -The role of corticosteroids is unknown. 2) ASCIA Action Plan for Anaphylaxis (red) required -It is reasonable to give a single dose of steroid (oral (www.allergy.org.au) prednisolone 1-2mg/kg (max 60mg) or IV hydrocortisone 3) Follow up plan as discussed with Immunology team 4mg/kg max 100mg) if there is persistent bronchospasm or a history of asthma

Date of Publishing: 19 June 2020 1:14 PM

Date of Printing:

Page 3 of 16

K:\CHW P&P\ePolicy\Jun 20\Anaphylaxis and GAR.docx This Guideline may be varied, withdrawn or replaced at any time.



TABLE OF CONTENTS

Algorithm	3
Clinical Definitions	5
Anaphylaxis	5
Symptoms/signs of respiratory/cardiovascular involvement are:	5
Generalised Allergic Reaction (GAR)	6
Diagnosis	6
Pathophysiology	6
Treatment of Anaphylaxis	7
Additional therapy:	8
Anti-Histamines	9
Steroids	9
Treatment of Generalised Allergic Reactions (GAR)	.9
Observation	10
Admission	
Discharge from hospital	
Follow up	
References	
Appendix 1: Hospital in the home (HITH) - Management of anaphylaxis	
Patients Receiving Medication At Home	
Preparing for home visit	
Each anaphylaxis kit contains:	
At the home visit	
Anaphylaxis or GAR	
Appendix 2: ASCIA Action plan for Anaphylaxis	
Appendix 3	16
EpiPen®	16



Clinical Definitions

Definitions of anaphylaxis vary considerably. For the purpose of this guideline we will use the Australasian Society of Clinical Immunology and Allergy (ASCIA) definitions of Anaphylaxis and Generalised Allergic Reaction: [ASCIA]

Anaphylaxis

Anaphylaxis has been defined as:

- Any acute onset illness with typical skin features (urticarial rash or erythema/flushing, and/or angioedema) PLUS any one or more of the following
 - o involvement of respiratory
 - o cardiovascular
 - o persistent severe gastrointestinal symptoms

OR

• Any acute onset of hypotension or bronchospasm or upper airway obstruction where <u>anaphylaxis is considered possible</u>, even if typical skin features are not present.

Symptoms/signs of respiratory/cardiovascular involvement are:

Respiratory:

- o Difficulty/noisy breathing
- Swelling of tongue
- o Swelling/tightness in throat or tightness in chest
- o Difficulty talking and/or hoarse voice
- o Dysphagia
- Wheeze or persistent cough
- o Cyanosis

Cardiovascular:

- Loss of, or altered consciousness or collapse
- o Dizziness
- Pallor and floppiness (in young children)
- o Hypotension
- Cardiac arrest

Gastrointestinal:

These are signs of anaphylaxis if reaction is to insect stings or injected medications

- Severe and persistent vomiting
- Severe and persistent abdominal pain



Generalised Allergic Reaction (GAR)

A reaction characterized by one or more symptoms or signs of skin and/or gastrointestinal tract involvement <u>without</u> respiratory and/or cardiovascular involvement.

<u>Skin:</u>

- o Generalised pruritus
- Urticaria / Angioedema
- o Generalised erythema

Gastrointestinal*:

- Abdominal pain
- o Vomiting
- o Diarrhoea
- o Nausea

*These are signs of anaphylaxis for reactions to insect stings or injected medications

Diagnosis

- The diagnosis of anaphylaxis and GAR is clinical. Use the ASCIA definitions above as a guide.
- Investigations have little role in acute diagnosis and management.
- A serum mast cell tryptase level (3mL in a 'red top' clotted blood tube) may be ordered in consultation with senior staff within 4 hours of onset of symptoms. Tryptase level is often normal in food related anaphylaxis.
- While urticaria and angioedema are commonly associated with anaphylaxis, they may be absent in up to 20% of presentations. A differential diagnosis of anaphylaxis must be considered in any case of acute onset respiratory distress, bronchospasm, hypotension, or cardiac arrest. GARs involving generalised erythema, urticaria, periorbital oedema or angioedema without signs of respiratory or, cardiovascular involvement do not constitute anaphylaxis.

Pathophysiology

- Most reactions occur within 30 minutes of exposure to a trigger but can occur up to 4 hours later.
- Anaphylaxis is an acute, rapidly progressive, potentially life-threatening immediate hypersensitivity triggered by histamine and other chemical mediators released from mast cells due to surface bound specific-IgE.
- A non-IgE mediated anaphylactic reaction (previously called anaphylactoid reactions) may have similar symptoms; however mediator release occurs independent of IgE



binding to mast cells. There is no practical difference in the acute management of these conditions.

- Multiple organ systems are affected, and at its most severe, anaphylaxis is characterised by bronchospasm, airway angioedema, and hypotension.
- A careful history is most helpful in trying to identify a possible allergen.
- The commonest causes of anaphylaxis in children are:
 - o foods (peanut, tree nuts, cow's milk, egg, soy, shellfish, fish, wheat),
 - o medications (beta lactam antibiotics),
 - o insect venom (bee, wasp, ant)

Treatment of Anaphylaxis

- Remove allergen if present
- Posture: do not allow child to stand or walk. Treat the child in the supine position, or the left lateral position for a vomiting child, or sitting upright if breathing is difficult, but monitor for hypotension.
- Immediate administration of IM adrenaline. Dose is 10micrograms/kg given as:
 - 0.01 mL/kg of 1:1000 (1mg/mL) adrenaline intramuscularly into the anterolateral thigh
 - Maximum dose = 0.5 mL of 1:1000 (1mg/mL)
- Use an EpiPen if unable to calculate exact dose or to avoid delay, including in children
 <1 year old (Epipen 300microg for children ≥20kg and Epipen 150microg for children 7.5-20kg)
- Further doses of IM adrenaline may be given every 5 minutes for persistent or recurring symptoms of anaphylaxis
- ICU consultation if \geq 2 doses adrenaline with inadequate effect



Age (years)	Weight (kg)	Volume of adrenaline (1:1000) mL	Adrenaline Autoinjectors
<1	<10	0.05-0.1	7.5-20kg
1-2	10	0.1	(~1-5 years)
2-3	15	0.15	150microg (green labelled) device
4-6	20	0.2	≥20kg
7-10	30	0.3	(~>5 years)
10-11	40	0.4	300microg (yellow labelled) device
≥12 and adults	>50	0.5	

Adrenaline Dosage Chart

- Get senior medical advice as needed
- A safe option to avoid difficult small volume adrenaline administration, is to deliver a minimum dose of 0.15mL of 1:1000 adrenaline to all children < 15 kg in estimated weight, otherwise the dose is 0.01mL/kg of 1:1000 adrenaline to a maximum of 0.5mL of 1:1000. To facilitate this an 'anaphylaxis kit' containing 1mL syringes, ampoules of 1:1000 adrenaline and sterile antiseptic wipes should be considered.
- Airway Supplemental Oxygen
 - Nebulised adrenaline may also be considered for stridor. Give 5mL of 1:1000 (1mg/mL) adrenaline [or 0.5mL/kg/dose of 1:1000 adrenaline if <10kg].
 - Do not delay endotracheal intubation if evolving airway obstruction
 - o If airway threatened then call
 - CODE BLUE (2222 at SCH and CHW)
- Breathing <u>Salbutamol via spacer or nebuliser</u> if wheeze (after giving IM adrenaline)
- Circulation large bore IV access if hypotensive/poorly perfused, give 0.9% sodium chloride fluid bolus 20 mL/kg and repeat if needed.
- Only allow to mobilise under observation ≥ 1 hour after last dose of adrenaline *and* once all symptoms resolved

Additional therapy:

- Oral non-sedating antihistamine once patient stable and able to tolerate
- Steroids as indicated see note below

Guideline: Anaphylaxis and Generalised Allergic Reaction (GAR)



• ICU consultation and adrenaline infusion if more than 2 doses of IM adrenaline are required and/or persistent hypotension.

Anti-Histamines

- In a child with anaphylaxis, antihistamines should only be given *after* the administration of adrenaline
- Oral antihistamines can be used to reduce cutaneous symptoms. Antihistamines do not treat or prevent anaphylaxis.

Age	Anti-histamine	Dose
6-12 months	Desloratadine	1mg once daily
1-2 years	Loratadine	2.5mg once daily
>2 years and <30kg	Loratadine	5mg once daily
>30kg	Loratadine	10mg once daily

- Sedating antihistamines should be avoided
- Parenteral (IVI or IMI) promethazine (Phenergan) should not be used in anaphylaxis as it may worsen vasodilation and hypotension and can cause muscle necrosis.

Steroids

- There is little evidence to support the use of corticosteroids including in the prevention of biphasic reactions, however, may be used at the discretion of the treating physician.
- Steroids have a theoretical place in severe anaphylactic reactions in children where bronchospasm is a major feature or where there is a background history of asthma.
- Corticosteroid can be given as oral prednisolone (1-2 mg/kg/dose up to 60mg) as per Asthma Management Guidelines or as intravenous hydrocortisone (4 mg/kg/dose up to 100mg) as stat doses.

Treatment of Generalised Allergic Reactions (GAR)

- GARs are mild to moderate allergic reactions without respiratory or cardiovascular involvement and are not life-threatening.
- If a child has gastrointestinal symptoms and the trigger is venom or an injected drug <u>this</u> <u>constitutes anaphylaxis</u> and requires treatment with adrenaline. If in doubt discuss the case with the patient's consultant (hospital inpatients including HITH), ED Consultant (ED patients) or Immunologist on-call (any patient).



- Allergens may be ingested, inhaled or come into contact with the skin. The mode of contact may influence the extent of the reaction.
- Urticaria persisting more than 24 hours is usually not due to an allergic reaction, unless repeated exposure to the allergen has occured.
- Angioedema is common; however, without signs of airway involvement (see <u>definition of</u> <u>anaphylaxis</u> above) does not equal anaphylaxis and can be managed as a GAR.
- GARs can be managed with a non-sedating antihistamine:

Age	Anti-histamine	Dose
6-12 months	Desloratadine	1mg once daily
1-2 years	Loratadine	2.5mg once daily
>2 years and <30kg	Loratadine	5mg once daily
>30kg	Loratadine	10mg once daily

- The patient must be monitored for the development of respiratory or cardiovascular involvement, as some patients with rapidly progressive symptoms will benefit from the early administration of adrenaline.
- Children with symptoms of a GAR do not need to be discussed with the immunology team unless there are specific management concerns.

Observation

- All patients who have had an anaphylactic reaction should be observed for a minimum of 4 hours post adrenaline.
- Only allow to mobilise under observation ≥ 1 hour after last dose of adrenaline and once all symptoms have resolved.
- <u>All children who are treated for anaphylaxis should have their case discussed with the immunology team</u>; the immunology fellow during the day and on-call immunologist after hours. If the patient is stable and there are no acute management concerns the immunologist may be contacted the following day to discuss ongoing management and follow up.

Admission

- Admissions should be discussed with the ED consultant or fellow.
- Indications for admission include:
 - Anaphylaxis requiring more than 1 dose of adrenaline or a fluid bolus
 - Anaphylaxis requiring 1 dose of adrenaline, but with residual features/symptoms of a GAR (other than isolated cutaneous symptoms) 4-6 hours post adrenaline

Guideline: Anaphylaxis and Generalised Allergic Reaction (GAR)



- Social concerns or senior ED staff concerns
- Admission may also be considered for children on regular beta blocker medication.
- Admissions can be:
 - Under the emergency team
 - To the Emergency Medicine Unit (EMU) at CHW
 - As a short stay admission at SCH
 - Under the immunology team to the ward

Consider ICU consultation for cases refractory to management.

Discharge from hospital

- **1.** All children who are treated for anaphylaxis should have their case discussed with the immunology team as soon as practical regarding follow up.
- **2.** a) For <u>ED patients</u> treated for anaphylaxis: If stable following 4 hours of observation after the last dose of adrenaline, a patient may be discharged from the ED.

b) For <u>inpatients</u> treated for anaphylaxis: If stable following 4 hours of observation after the last dose of adrenaline, a patient may be discharged from hospital *after* discussion with the admitting staff specialist, if there are no other reasons to remain in hospital.

- **3.** Before discharge all children who have presented with anaphylaxis should have a plan to obtain a prescription for an EpiPen, as soon as practically possible, which can be arranged after discussion with the immunology team. An Epipen prescription should be given with EpiPen training and an ASCIA Action Plan for Anaphylaxis (red plan, available at http://www.allergy.org.au/health-professionals/ascia-plans-action-and-treatment).
- **4.** Children presenting with a GAR do not need an EpiPen and should be discharged home with an ASCIA Action Plan for Allergic Reactions (green plan, available at http://www.allergy.org.au/health-professionals/ascia-plans-action-and-treatment).
- Parent information sheets about anaphylaxis in multiple languages can be found on the ASCIA website (<u>https://allergy.org.au/hp/anaphylaxis/</u>) and SCHN intranet (<u>https://www.schn.health.nsw.gov.au/fact-sheets/category/#cat10</u>)

Follow up

All patients need a clear plan regarding follow up when discharged from hospital and/or the ED.

<u>All children presenting with anaphylaxis:</u> A discharge letter for their GP & a referral letter for the Immunology clinic addressed to the Immunology consultant on call [ie: the person you spoke to].



<u>All children presenting with a GAR:</u> a discharge letter for their GP & a referral letter for a general paediatrician. Referrals to the allergy clinic at both SCH and CHW, for non-anaphylactic reactions can only be made by a paediatrician.

Any child may be seen by a private paediatrician or immunologist/allergist if their parents and GP wish to refer.

References

1. Australian Society for Clinical Immunology and Allergy, ASCIA Action Plans and Checklists. <u>http://www.allergy.org.au/health-professionals/ascia-plans-action-and-treatment</u> (accessed 19/05/2015)

2. Australian Department of Health, Pharmaceutical Benefits Scheme, Adrenaline, <u>http://www.pbs.gov.au/medicine/item/3409K-8698T</u> (accessed 19/05/2015)

Copyright notice and disclaimer:

The use of this document outside Sydney Children's Hospitals Network (SCHN), or its reproduction in whole or in part, is subject to acknowledgement that it is the property of SCHN. SCHN has done everything practicable to make this document accurate, up-to-date and in accordance with accepted legislation and standards at the date of publication. SCHN is not responsible for consequences arising from the use of this document outside SCHN. A current version of this document is only available electronically from the Hospitals. If this document is printed, it is only valid to the date of printing.



Appendix 1: Hospital in the home (HITH) - Management of

anaphylaxis

Patients Receiving Medication At Home

The nurses working for the hospital in the home (HITH) administer antibiotics and other medications in the home. This protocol is a guide to assist the HITH nurse in the administration of intramuscular adrenaline in the event of an anaphylactic reaction during or following administration of intravenous medications in accordance with this policy.

Children with the following conditions are excluded from receiving medications at home.

- History of mastocytosis
- Previous adverse reactions to the prescribed medication
- Currently taking beta-blocker medication (adrenaline may not be effective)

Preparing for home visit

- The HITH nurse responsible for direct patient care must have received training and is competent in recognition and treatment of anaphylaxis in paediatric patients.
- Every child transferred to HITH will receive the first dose of medication in the hospital setting.
- The HITH handover sheet to have contact details for treating team, in case of emergency.
- Ensure:
 - An **anaphylaxis kit** is taken on all visits where a child needs to be given medication (including all oral, IV, IM or subcutaneous medications).
 - An anaphylaxis kit can be obtained from pharmacy. Each HITH nurse will hold one kit per work bag. When you have used the kit it can be replaced by pharmacy.
 - An order for PRN IM adrenaline and oral anti-histamine is required, along with orders for the medication/s to be administered by HITH staff, on the child's medication administration record (MAR) *before* any home visit.

Each anaphylaxis kit contains:

- o 2x Epipen 150micrograms (for patients 7.5-20kg)
- o 2x Epipen 300micrograms (for patients ≥20kg)
- Loratadine 1mg/mL syrup
- Desloratadine syrup
- o Salbutamol (Asmol) 100microgram/puff inhaler 200 dose
- Spacer device
- Oral syringes x 1 size 5mL and 10mL
- Disposable resuscitator

Guideline No: 2015-9066 v2 Guideline: Anaphylaxis and Generalised Allergic Reaction (GAR)



- Drug dose card
- 1 x general ASCIA Action Plan for anaphylaxis (see <u>Appendix 2</u> below)

At the home visit

- Follow the procedure for administration of the prescribed medication.
- Check the five rights: route, drug, dose, patient name and time.
- Watch for signs of adverse reactions

Anaphylaxis or GAR

- If you suspect an allergic reaction, follow the ASCIA action plan for anaphylaxis (appendix 2)
- If the child develops any one of the signs of anaphylaxis give adrenaline by administering the EpiPen
 - EpiPen Jr (150micrograms) if <20kg or
 - EpiPen (300micrograms) if ≥20kg
- In the event of immediate threat to life due to anaphylaxis consider EpiPen Junior for infants <10kg
- After giving adrenaline **ask the parent or a responsible adult to call an ambulance (000)**. All children who have received adrenaline should be transferred by ambulance to the ED for a minimum of 4 hours observation.
- As per the ASCIA Action Plan further doses of adrenaline may be given after 5 minutes if the symptoms of anaphylaxis have recurred or are persisting.
- Anti-histamines: In a child with anaphylaxis, antihistamines should only be given *after* the administration of adrenaline
- Oral antihistamines can be used to reduce cutaneous symptoms. They do <u>not</u> treat or prevent anaphylaxis. A non-sedating antihistamine may be given such as:


Age	Anti-histamine	Dose
6-12 months	Desloratadine	1mg once daily
1-2 years	Loratadine	2.5mg once daily
>2 years and <30kg	Loratadine	5mg once daily
>30kg	Loratadine	10mg once daily

• Always contact the child's medical team once the child is stable, complete IIMS and debrief with manager.



Appendix 2: ASCIA Action plan for Anaphylaxis

(for use by HITH nurses administering home IV medications)



Date of Publishing: 19 June 2020 1:14 PM K:\CHW P&P\ePolicy\Jun 20\Anaphylaxis and GAR.docx This Guideline may be varied, withdrawn or replaced at any time.



Appendix 3

EpiPen®

An EpiPen is a form of self-injectable adrenaline and comes as:

- EpiPen® (for children 20 kg and over, 1:1000, 300micrograms, single dose 2mL)
- EpiPen Jr® (for children under 20 kg, 1:2000, 150micrograms, single dose 2mL)

EpiPens cannot be prescribed from the Emergency Department without involvement of the immunologist on-call or Allergy CNC (but GP can prescribe according to the criterion "Authority Required: Initial sole PBS-subsidised supply for anticipated emergency treatment of acute allergic reactions with anaphylaxis in a patient who has been discharged from hospital or an emergency department after treatment with adrenaline for acute allergic reaction with anaphylaxis").

EpiPen® prescription must be accompanied by a comprehensive Anaphylaxis Management Plan including:

- Referral to an Immunologist.
- Training in when and how to use the EpiPen®.
- Identification of triggers if possible, through a thorough history.
- Education on avoidance of triggers, especially for food allergies.
- Provision of an Anaphylaxis Action Plan.

In Australia, EpiPen® is listed on the Pharmaceutical Benefits Scheme (PBS) as an authority only script. PBS indications for EpiPen® prescription are:

- Anaphylaxis as defined above.
- Where the patient has received adrenaline in the ED.

EpiPen may be considered in the following circumstances. This should always be discussed with the Immunologist on-call before the EpiPen® is prescribed:

- GAR with one or more of the following:
 - Asthma, current or past history
 - Specific nut allergy
 - Specific insect bite allergy
 - o Limited access to Emergency Medical Care (remote area).